查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2059317

感染疾病診斷市場：市場洞察、競爭格局與市場預測（2032 年）

Infectious Disease Diagnostics - Market Insights, Competitive Landscape, and Market Forecast - 2032
出版日期: | 出版商: DelveInsight | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

感染疾病診斷市場概述

  • 全球感染疾病診斷市場預計將從 2025 年的 283.3885 億美元成長到 2034 年的 381.55 億美元，展現出強勁且持續的成長動能。
  • 全球感染疾病診斷市場預計在 2026 年至 2034 年的預測期內將以 3.41% 的年複合成長率成長。
  • 結核病、流感、肝炎、愛滋病以及新出現的病毒感染疾病等感染疾病的盛行率不斷上升，顯著增加了全球對快速、準確診斷解決方案的需求。同時，患者和醫護人員的健康意識不斷提高，以及政府主導的篩檢和監測項目，促進了疾病的早期發現和定期檢測，從而擴大了感染疾病診斷的普及範圍。此外，診斷公司持續進行產品研發，包括推出先進的分子診斷技術、就地檢驗盒、人工智慧平台和多重檢測方法，提高了檢測的準確性、速度和可及性。這些因素共同推動了感染疾病診斷市場的成長，其成長動力來自檢測量的增加、醫療基礎設施的加強以及對疾病及時管理的支持，這在已開發地區和新興地區均有體現。
  • 在感染疾病診斷市場中營運的主要公司包括：羅氏製藥有限公司、雅培實驗室、Bio-Rad Laboratories, Inc.、丹納赫公司、賽默飛世爾科技公司、凱傑公司、生物梅里埃公司、西門子醫療股份公司、DiaSorin SpA、Hologic, Inc.、Sysmex Corporation、Quidel Corporation、Bioelidel Corporation、Bioconomel） Scientific、InfeXn Laboratories Pvt Ltd.、Aegis Sciences Corporation、Meridian Bioscience, Inc.、BD、OraSure Technologies, Inc.、Trinity Biotech plc、Chembio Diagnostics, Inc.、Sekisui Diagnostics、PerkinElmer, Inc.、Genbio Diagnostics, Inc.、Sekisui Diagnostics、PerkinElmer, Inc.、Genbio Diagnostics, Inc., G. Inc.、Mylab Discovery Solutions Pvt.、Molbio Diagnostics Pvt.有限公司、GenBody Inc. 等。
  • 北美地區感染疾病高發生率、主要廠商實力雄厚、醫療基礎設施先進，以及分子診斷和照護現場技術的應用日益普及，預計將成為感染疾病診斷市場的主要驅動力。此外，有利的政府政策、高額的醫療費用支出、人們對疾病早期檢測意識的不斷提高，以及持續的研發活動，都將進一步推動全部區域市場的成長。
  • 在按類型分類的感染疾病診斷市場中，預計到 2025 年，產品類型將佔據最大的市場佔有率。

推動感染疾病診斷市場成長的因素

  • 感染疾病的蔓延：結核病、愛滋病、肝炎、瘧疾和呼吸道感染疾病等感染疾病的激增，使得快速準確診斷的需求變得迫切。新冠肺炎、伊波拉、茲卡病毒和抗藥性細菌等新威脅的出現，進一步增加了對感染疾病診斷的需求。
  • 擴大宣傳活動和篩檢計畫：宣傳活動對於感染疾病防治至關重要，它透過社區教育、推廣預防措施以及加速早期診斷和治療來實現這一目標。世界各地都在實施針對各種感染疾病的宣傳項目，每個項目都旨在應對其各自獨特的挑戰。
  • 全球產品研發活動日益活躍：產品研發活動的增加顯著推動了感染疾病診斷市場的整體成長，促進了創新、提高了準確性並增強了可及性。各公司正大力投資開發能夠提供更快結果和更方便體驗的先進診斷工具，包括快速檢測、分子診斷和就地檢驗設備。這些創新滿足了人們對早期發現和及時治療日益成長的需求，而這對於控制疫情爆發和疾病傳播至關重要。

感染疾病診斷市場報告細分

本感染疾病診斷市場報告全面概​​述了全球感染疾病診斷市場，重點分析了關鍵趨勢、成長要素、挑戰和機會。報告按類型、技術、檢測類型、應用、最終用戶和地區進行了詳細的市場細分，並深入分析了北美、歐洲和亞太等主要市場的競爭格局、監管環境和市場動態。報告詳細介紹了主要產業參與企業及其最新產品創新，為企業提供關鍵數據，幫助其識別市場潛力、制定策略規劃，並掌握快速成長的感染疾病診斷市場中新興的機會。

感染疾病診斷市場包括用於檢測和識別致病病原體的診斷測試、檢測方法和設備。

結核病、流感、肝炎、愛滋病、新冠肺炎、登革熱、瘧疾以及其他新出現的病毒和細菌性行為感染等感染疾病的日益流行，顯著增加了全球對快速、可靠和準確的診斷解決方案的需求。慢性病和感染疾病負擔的惡化凸顯了早期診斷的必要性，以預防疾病傳播、改善患者預後並降低醫療成本。此外，新興和再發病原體的頻繁爆發，以及全球旅行和都市化進程的加快，進一步加速了醫院、診斷檢查室、診所和居家醫療機構對高效感染疾病監測和檢測系統的需求。

同時，患者、醫護人員和公共衛生組織對早期疾病檢測和預防醫學重要性的認知不斷提高，推動了感染疾病診斷檢測的擴展。各國政府和世界衛生組織正日益實施大規模篩檢措施、疫苗接種監測計畫、公共衛生宣傳活動和疾病監測策略，以遏制感染傳播並加強醫療衛生系統。這些努力在開發中國家的重要優先事項。

此外，診斷設備製造商持續的產品研發和技術進步正在改變感染疾病診斷領域。各公司積極採用先進的分子診斷技術，例如基於PCR的檢測方法、次世代定序（NGS）、多檢測平台、人工智慧驅動的診斷系統、自動化分析儀以及能夠快速提供檢測結果的就地檢驗盒。這些技術帶來了更快的檢測速度、更高的靈敏度和更強的診斷準確性。數位健康技術和攜帶式診斷設備的日益整合也改善了偏遠和資源匱乏地區獲得檢測的機會。這些因素共同推動了感染疾病診斷市場的顯著成長，其成長體現在檢測量的增加、醫療基礎設施的改善、更及時的臨床決策以及對已開發地區和新興地區有效疾病管理的支持等方面。

感染疾病診斷市場的最新市場動態和趨勢是什麼？

感染疾病上升，加上公眾意識增強和篩檢計畫擴大，推動了對快速準確診斷解決方案的需求。隨著越來越多的人接受定期檢測，對可靠診斷工具的需求也在增加。此外，全球產品研發的活性化推進了診斷技術的發展，並提高了檢測的準確性、速度和可及性。

根據世界衛生組織（世衛組織）提供的最新統計數據

  • 結核病（TB）：據估計，到2024年，全球將有1,070萬人感染結核病。診斷在快速識別活動性結核病病例、實現早期治療和降低感染風險方面發揮著至關重要的作用。使用結核菌素皮膚試驗和干擾素釋放檢測法（IGRA）等工具篩檢潛伏性結核感染（LTBI）有助於預防疾病活化。核酸增幅檢查（NAAT）等分子技術能夠快速檢測包括抗藥性菌株在內的各種結核病，並指導適當的治療，從而推動了感染疾病診斷市場的發展。
  • 肝炎：據估計，2022年全球約有2.54億人患有B型肝炎，5000萬人患有C型肝炎，每天新增病毒性肝炎感染病例約6000例。感染疾病診斷技術使得早期檢測肝炎（甲型、乙型、丙型、丁型和戊型肝炎）成為可能，通常在症狀出現之前即可檢測到。早期診斷對於預防疾病進展和控制感染至關重要。血液檢測、肝功能檢測和血清學檢測透過檢測抗原、抗體或病毒遺傳物質（例如，乙型肝炎病毒DNA或丙型肝炎病毒RNA）來識別特定的肝炎病毒，從而推動了全球感染疾病診斷市場的整體發展。
  • 愛滋病毒：到2024年，全球約有130萬人（100萬至170萬人）將感染愛滋病毒。愛滋病毒診斷檢測通常與其他性行為感染感染（STI）的檢測同時進行，例如梅毒和肝炎。這種綜合檢測推動了對多疾病診斷平台的需求。
  • 流感：2024年，全球約有10億例季節性流感病例，其中300萬至500萬例為重症。快速流感診斷測試（RIDT）可快速診斷流感，但更先進的技術，例如逆轉錄聚合酶鍊式反應（RT-PCR）和其他核酸增幅檢查（NAAT），具有更高的準確性。此外，病毒培養和血清學檢測有助於確診感染和研究免疫反應。

因此，快速診斷檢測（RDT）、核酸增幅檢查（NAAT）和照護現場（POC​​）的發展提高了檢測的可及性和準確性，從而推動了市場成長。此外，抗生素抗藥性的日益嚴重迫使醫療系統優先考慮病原體的早期識別，並確保及時介入。將診斷納入常規健康檢查的趨勢以及多參數檢測的日益普及，進一步擴大了感染疾病診斷市場。

此外，產品研發活動的活性化進一步推動了感染疾病診斷市場的整體成長。 2025年1月，領先的按需和居家診斷檢測及檢體管理解決方案提供商OraSure Technologies, Inc.宣布，美國食品藥物管理局（FDA）生技藥品評估和研究中心（CBER）已核准OraQuick® HIV自檢試劑盒的標籤變更，從而擴大了青少年獲得HIV檢測的機會。

因此，由於上述因素，預計感染疾病診斷市場整體將在預測期內擴張。

然而，檢體在運輸和儲存過程中受到污染的風險是感染疾病診斷市場面臨的主要阻礙因素。這會降低檢測結果的準確性和可靠性，可能導致假陽性、假陰性或不確定結果。不當處理、包裝不當、溫度波動、滅菌程序不完善以及低溫運輸管理薄弱都會損害檢體完整性，影響診斷性能，尤其是在PCR等分子檢測中。此外，運輸時間過長、處理程序不一致以及發展中地區醫療基礎設施不足會進一步增加污染風險。這些挑戰會延誤疾病檢測、增加營運成本並降低人們對診斷檢測的信心，最終阻礙預測期內的市場成長。

感染疾病診斷市場細分分析

感染疾病診斷市場：按類型、技術、檢測類型、應用、最終用戶和地區分類

感染疾病診斷市場區域分析

北美感染疾病診斷市場趨勢

預計到2025年，北美將佔據感染疾病診斷市場41%的最大佔有率，成為所有地區中市場佔有率最高的地區。北美之所以可望主導感染疾病診斷市場，主要原因在於其感染疾病高發生率、主要廠商實力雄厚、醫療基礎設施先進，以及分子診斷和照護現場技術的日益普及。此外，有利的政府政策、高額的醫療費用支出、人們對疾病早期檢測意識的不斷提高，以及持續的研發活動，都進一步推動了全部區域市場的成長。

根據美國衛生與公共服務部（2025 年）提供的數據，每年約有 2,300 萬美國人前往診所和醫療機構尋求感染疾病治療。

此外，根據美國疾病管制與預防中心（CDC，2026年）的估計，美國有超過120萬人感染愛滋病毒，2024年新增確診病例約3.9萬例。病毒性流感、愛滋病毒和B型肝炎等感染疾病在美國的盛行率不斷上升，將推動感染疾病診斷檢測的需求增加。有效治療和控制感染傳播需要快速發現更多病例，這將導致醫院、診所和實驗室的檢測量增加。診斷技術的進步和公共衛生政策的改善將進一步增加對快速準確檢測的需求，以預防疫情爆發並改善患者預後。

此外，感染疾病診斷領域的各種產品開發和上市活動將進一步加速市場成長。 2023年12月，QuidelOrtho公司宣布其Savanna PCR平台和Savanna HSV 1+2/VZV檢測已獲得美國FDA的510(k)核准。本平台和檢測試劑盒能夠利用病灶部位的拭子檢體檢測和區分HSV-1、HSV-2和VZV。獲得核准後，QuidelOrtho公司現在可以向美國進行中等至高度複雜診斷檢測的實驗室銷售該平台和檢測套組。

因此，預計上述所有因素將在 2026 年至 2034 年的預測期內推動美國感染疾病診斷市場的發展。

歐洲感染疾病診斷市場趨勢

受感染疾病流行率上升、政府對疾病監測日益重視以及先進分子診斷和照護現場診斷技術日益普及的推動，歐洲感染疾病診斷市場正經歷強勁且持續的成長。該地區擁有完善的醫療基礎設施、有利的報銷政策以及對研發的大力投入。此外，醫院感染（HAI）和抗菌素抗藥性的日益嚴重，以及對快速、準確診斷解決方案需求的成長，進一步推動了歐洲市場的擴張。領先企業的存在以及PCR、多重檢測和基因組檢測技術的不斷進步也加速了市場成長。此外，近期產品核可也增強了區域市場實力。例如，2024年9月，QIAGEN的QIAstat-Dx症候群檢測系統和呼吸道及胃腸道感染疾病檢測板獲得了歐洲體外診斷醫療器材法規（IVDR）認證。同樣，2024年，羅氏診斷的新型多重呼吸道檢測板（用於檢測流感、呼吸道合胞病毒（RSV）和SARS-CoV-2變種）獲得了CE認證。這些發展趨勢共同推動了歐洲感染疾病診斷市場的成長。

亞太地區感染疾病診斷市場趨勢

由於感染疾病流行率上升、人口基數不斷成長、醫療保健支出增加，以及中國、印度和東南亞等發展中國家診斷服務可近性的提高，亞太地區正成為感染疾病的開發中國家。該地區各國政府正積極加強疾病監測系統，並投資醫療基礎設施，以提高疾病早期發現和疫情控制能力。此外，人們對傳染病篩檢意識的提高、分子診斷和就地檢驗的推廣，以及國內外診斷設備製造商的日益增多，都進一步加速了市場成長。快速的都市化、醫療旅遊的興起，以及旨在防治結核病、登革熱、肝炎、流感和新冠肺炎等疾病的公共衛生措施，也顯著推動了亞太地區感染疾病診斷市場的擴張。

感染疾病診斷市場的主要參與者有哪些？

以下是感染疾病診斷市場的主要參與者。這些公司通常佔據最大的市場佔有率，並引領行業趨勢。

  • Hoffmann-La Roche Ltd.
  • Abbott Laboratories
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation
  • Thermo Fisher Scientific Inc.
  • QIAGEN
  • bioMerieux
  • Siemens Healthineers AG
  • DiaSorin SpA
  • Hologic, Inc.
  • Sysmex Corporation
  • QuidelOrtho Corporation
  • Biosynex SA
  • Cardinal Health
  • Laboratory Corporation of America Holdings
  • Eurofins Scientific
  • InfeXn Laboratories Pvt Ltd.
  • Aegis Sciences Corporation
  • Meridian Bioscience, Inc.
  • BD
  • OraSure Technologies, Inc.
  • Trinity Biotech plc
  • Chembio Diagnostics, Inc.
  • Sekisui Diagnostics
  • PerkinElmer, Inc.
  • GenMark Diagnostics, Inc.
  • Seegene Inc.
  • Fujirebio Holdings, Inc.
  • Arkray, Inc.
  • SD Biosensor, Inc.
  • Mylab Discovery Solutions Pvt. Ltd.
  • Molbio Diagnostics Pvt. Ltd.
  • GenBody Inc.
  • 其他

感染疾病診斷市場的競爭格局是如何形成的？

感染疾病診斷市場的競爭格局極為活躍，全球和區域性參與企業之間的競爭異常激烈，它們專注於技術創新、產品開發、策略聯盟、併購和地理擴張。羅氏、雅培、賽默飛世爾科技、凱傑和生物梅里埃等領導企業正積極投資於先進的分子診斷、多重檢測、PCR技術和就地檢驗解決方案，以鞏固其市場地位。各公司也致力於開發快速自動化診斷平台，旨在提高檢測準確性、縮短反應時間並支援大規模疾病篩檢。此外，監管核准的增加、與醫療機構的合作以及向新興市場的擴張也加劇了市場競爭。人工智慧整合診斷、症候群特異性檢測組合和分散式檢查解決方案日益受到關注，這進一步塑造了競爭格局，並推動了整個感染疾病診斷市場的創新。

感染疾病診斷市場近期趨勢

  • 2025 年 1 月，現場和家庭診斷測試及檢體管理解決方案的領導者 OraSure Technologies, Inc. 宣布，美國食品藥物管理局(FDA)生技藥品評估和研究中心 (CBER) 已核准OraQuick® HIV 自檢試劑的標籤變更，從而擴大了青少年獲得 HIV 檢測的機會。

感染疾病診斷市場的市場區隔

  • 感染疾病診斷市場按類型分類
  • 產品
  • 裝置
  • 試劑和試劑盒
  • 服務
  • 利用科技進行感染疾病診斷
  • 分子診斷
  • 聚合酵素鏈鎖反應（PCR）
  • DNA定序與次世代定序（NGS）
  • 核酸增幅檢查（NAAT）
  • 其他
  • 免疫診斷
  • 微生物培養
  • 其他
  • 感染疾病診斷測試和暴露類型
  • 檢查室測試
  • 測試類型，測試環境
  • 為診斷感染疾病而進行的暴露
  • 病毒性疾病
  • 細菌性疾病
  • 其他
  • 終端用戶感染疾病診斷
  • 醫院
  • 診斷檢查室
  • 其他
  • 感染疾病診斷的區域趨勢
  • 北美感染疾病診斷市場
  • 美國感染疾病診斷市場
  • 加拿大感染疾病診斷市場
  • 墨西哥感染疾病診斷市場
  • 歐洲感染疾病診斷市場
  • 英國感染疾病診斷市場
  • 德國感染疾病診斷市場
  • 法國感染疾病診斷市場
  • 義大利感染疾病診斷市場
  • 西班牙感染疾病診斷市場
  • 其他歐洲感染疾病診斷市場
  • 亞太地區感染疾病診斷市場
  • 中國感染疾病診斷市場
  • 日本感染疾病診斷市場
  • 印度感染疾病診斷市場
  • 澳洲感染疾病診斷市場
  • 韓國感染疾病診斷市場
  • 亞太地區其他感染疾病診斷市場
  • 其他區域感染疾病診斷市場
  • 南美洲感染疾病診斷市場
  • 中東感染疾病診斷市場
  • 非洲感染疾病診斷市場

感染疾病診斷市場報告要點。

  • 對感染疾病診斷市場的當前市場規模（2025 年）進行分析，並進行 8 年市場預測（2026 年至 2034 年）。
  • 過去三年發生的主要產品和技術開發、併購、合作和合資企業
  • 主導感染疾病診斷市場的主要公司
  • 感染疾病診斷市場為其他競爭對手提供了各種機會
  • 哪些細分市場在2025年表現最佳？這些細分市場在2034年又會呈現哪些趨勢？
  • 目前哪些地區、國家在感染疾病診斷市場表現最佳？
  • 企業應專注於哪些地區和國家，以尋求感染疾病診斷市場的未來成長機會？

關於感染疾病診斷市場的常見問題

1.感染疾病診斷市場的成長率是多少？

  • 預計從 2026 年到 2034 年的預測期內，感染疾病診斷市場將以 3.41% 的年複合成長率成長。

2.感染疾病診斷市場規模有多大？

  • 全球感染疾病診斷市場預計將從 2025 年的 283.3885 億美元成長到 2034 年的 381.55 億美元。

3. 哪個地區在感染疾病診斷市場中佔據最大的市場佔有率？

  • 北美地區感染疾病高發生率、主要廠商實力雄厚、醫療基礎設施先進，以及分子診斷和照護現場技術的應用日益普及，預計將成為感染疾病診斷市場的主要驅動力。此外，有利的政府政策、高額的醫療費用支出、人們對疾病早期檢測意識的不斷提高，以及持續的研發活動，都將進一步推動全部區域市場的成長。

4.感染疾病診斷市場的成長要素為何？

  • 結核病、流感、肝炎、愛滋病和新興病毒感染疾病等感染疾病的日益流行，正推動全球對快速、精準診斷解決方案的需求顯著成長。同時，患者和醫護人員的健康意識不斷提高，以及政府主導的篩檢和監測項目，促進了疾病的早期發現和定期檢測，從而加速了個別化感染疾病診斷方法的普及。此外，診斷公司持續進行產品研發活動，包括推出先進的分子診斷技術、就地檢驗盒、人工智慧平台和多重檢測方法，正在提升檢測的準確性、速度和可近性。這些因素共同推動了感染疾病診斷市場的成長，其成長動力來自檢測量的增加、醫療基礎設施的加強以及對疾病及時管理的支持，這在已開發地區和新興地區均有體現。

5.感染疾病診斷市場的主要企業有哪些？

  • 感染疾病診斷市場的主要參與企業包括：羅氏製藥有限公司、雅培實驗室、Bio-Rad Laboratories, Inc.、丹納赫公司、賽默飛世爾科技公司、凱傑公司、生物梅里埃公司、西門子醫療股份公司、DiaSorin SpA、Hologic, Inc.、Sysmex Corporation、Quidel Corporation, Oidel Corporation、Bioidynt. Scientific、InfeXn Laboratories Pvt Ltd.、Aegis Sciences Corporation、Meridian Bioscience, Inc.、BD、OraSure Technologies, Inc.、Trinity Biotech plc、Chembio Diagnostics, Inc.、Sekisui Diagnostics、PerkinElmer, Inc.、Genbio Diagnostics, Inc.、Sekisui Diagnostics、PerkinElmer, Inc.、Genbio Diagnostics, Inc., G. Inc. 和 Mylab Discovery Solutions Pvt.例如 Ltd.、Molbio Diagnostics Pvt. Ltd. 和 GenBody Inc.。

目錄

第1章：感染疾病診斷市場報告概述

第2章：感染疾病診斷市場執行摘要

第3章：感染疾病診斷市場關鍵因素分析

  • 推動感染疾病診斷市場發展的因素
    • 感染疾病的傳播
    • 意識提升並加強篩檢計劃
    • 全球範圍內的產品開發活動日益增多。
  • 阻礙感染疾病診斷市場發展的因素與挑戰。
    • 運送和儲存過程中樣品污染的風險
  • 感染疾病診斷市場的機遇
    • 我們將利用人工智慧（AI）和機器學習（ML）來分析診斷數據。

第4章 影響分析：人工智慧、地緣政治、貿易和經濟趨勢

第5章：監理分析

  • 美國
  • 歐洲
  • 日本
  • 中國

第6章：感染疾病診斷市場的波特五力分析

第7章：感染疾病診斷市場評估

  • 按類型
    • 產品
    • 服務
  • 透過技術
    • 分子診斷
    • 免疫診斷
    • 微生物培養
    • 其他
  • 按測試類型
    • 臨床檢查室的檢測
    • 照護現場偵測 (POC)
  • 透過使用
    • 病毒性疾病
    • 細菌性疾病
  • 最終用戶
    • 醫院
    • 診斷檢查室
  • 按地區
    • 北美洲
    • 歐洲
    • 亞太地區
    • 其他地區

第8章 競爭情勢

第9章：新創企業資金籌措與投資趨勢

第10章：感染疾病診斷市場中的公司與產品概況

  • Hoffmann-La Roche Ltd
  • Abbott Laboratories
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation
  • Thermo Fisher Scientific Inc.
  • QIAGENbioMerieux
  • Siemens Healthineers AG
  • DiaSorin SpA
  • Hologic, Inc.
  • Sysmex Corporation
  • QuidelOrtho Corporation
  • Biosynex SA
  • Cardinal Health
  • Laboratory Corporation of America Holdings
  • Eurofins Scientific
  • InfeXn Laboratories Pvt Ltd.
  • Aegis Sciences Corporation
  • Meridian Bioscience, Inc.
  • BD
  • OraSure Technologies, Inc.
  • Trinity Biotech plc.
  • Chembio Diagnostics, Inc.
  • Sekisui Diagnostics
  • PerkinElmer, Inc.
  • GenMark Diagnostics, Inc.
  • Seegene Inc.
  • Fujirebio Holdings, Inc.
  • Arkray, Inc.
  • SD Biosensor, Inc.
  • Mylab Discovery Solutions Pvt. Ltd.
  • Molbio Diagnostics Pvt. Ltd.
  • GenBody Inc..

第11章：KOL的觀點

第12章 專案方法

第13章：關於 DelveInsight

第14章 免責聲明與聯絡方式

Product Code: DIMDCL0565

Infectious Disease Diagnostics Market Summary

  • The global infectious disease diagnostics market is expected to increase from USD 28,338.85 million in 2025 to USD 38,155.00 million by 2034, reflecting strong and sustained growth.
  • The global infectious disease diagnostics market is growing at a CAGR of 3.41% during the forecast period from 2026 to 2034.
  • The rising prevalence of infectious diseases such as tuberculosis, influenza, hepatitis, HIV, and emerging viral infections is significantly increasing the demand for rapid and accurate diagnostic solutions worldwide. At the same time, growing awareness among patients and healthcare providers, along with government-led screening and surveillance programs, is encouraging early disease detection and routine testing, thereby expanding the adoption of infectious disease diagnostics. In addition, continuous product development activities by diagnostic companies, including the launch of advanced molecular diagnostics, point-of-care testing kits, AI-enabled platforms, and multiplex assays, are improving testing accuracy, speed, and accessibility. Collectively, these factors are driving the growth of the infectious disease diagnostics market by increasing testing volumes, enhancing healthcare infrastructure, and supporting timely disease management across both developed and emerging regions.
  • The leading companies operating in the infectious disease diagnostics market include Hoffmann-La Roche Ltd., Abbott Laboratories, Bio-Rad Laboratories, Inc., Danaher Corporation, Thermo Fisher Scientific Inc., QIAGEN, bioMerieux, Siemens Healthineers AG, DiaSorin S.p.A., Hologic, Inc., Sysmex Corporation, QuidelOrtho Corporation, Biosynex SA, Cardinal Health, Laboratory Corporation of America Holdings, Eurofins Scientific, InfeXn Laboratories Pvt Ltd., Aegis Sciences Corporation, Meridian Bioscience, Inc., BD, OraSure Technologies, Inc., Trinity Biotech plc, Chembio Diagnostics, Inc., Sekisui Diagnostics, PerkinElmer, Inc., GenMark Diagnostics, Inc., Seegene Inc., Fujirebio Holdings, Inc., Arkray, Inc., SD Biosensor, Inc., Mylab Discovery Solutions Pvt. Ltd., Molbio Diagnostics Pvt. Ltd., GenBody Inc., and others.
  • North America is expected to dominate the infectious disease diagnostics market due to the high prevalence of infectious diseases, strong presence of leading diagnostic companies, advanced healthcare infrastructure, and increased adoption of molecular and point-of-care diagnostic technologies. In addition, favorable government initiatives, high healthcare spending, rising awareness regarding early disease detection, and continuous research and product development activities are further supporting market growth across the region.
  • In the type segment of the infectious disease diagnostics market, the products category is estimated to account for the largest market share in 2025.

Factors Contributing to the Growth of the Infectious Disease Diagnostics Market

  • Rising prevalence of infectious diseases: The surge in infectious diseases such as tuberculosis (TB), HIV/AIDS, hepatitis, malaria, and respiratory infections has created a pressing need for timely and accurate diagnostics. Emerging threats like COVID-19, Ebola, Zika virus, and drug-resistant bacteria have further heightened the demand for infectious disease diagnostics.
  • Increased awareness and screening programs: Awareness programs are crucial in combating infectious diseases by educating communities, promoting preventive measures, and encouraging early diagnosis and treatment. Various infectious diseases have dedicated awareness programs globally, each aiming to address unique challenges.
  • Increase in product development activities across the globe: The increase in product development activities is significantly boosting the overall market of infectious disease diagnostics by driving innovation, improving accuracy, and enhancing accessibility. Companies are investing heavily in developing advanced diagnostic tools, such as rapid tests, molecular diagnostics, and point-of-care testing devices, which offer quicker results and greater convenience. These innovations address the growing demand for early detection and timely treatment, crucial for managing outbreaks and reducing disease transmission.

Infectious Disease Diagnostics Market Report Segmentation

This infectious disease diagnostics market report offers a comprehensive overview of the global infectious disease diagnostics market, highlighting key trends, growth drivers, challenges, and opportunities. It covers detailed market segmentation by Type (Products {Instruments and Reagents & Kits} and Services), Technology (Molecular Diagnostics {Polymerase chain reaction (PCR), DNA Sequencing and Next-Generation Sequencing (NGS), Nucleic Acid Amplification Tests (NAAT), and Others}, Immunodiagnostics, Microbial Cultures, and Others), Test Type (Laboratory-Based Tests and Point-of-Care (POC) Tests), Application (Viral Diseases, Bacterial Diseases, and Others), End-Users (Hospitals, Diagnostic Labs, and Others), and geography. The report provides valuable insights into the competitive landscape, regulatory environment, and market dynamics across major markets, including North America, Europe, and Asia-Pacific. Featuring in-depth profiles of leading industry players and recent product innovations, this report equips businesses with essential data to identify market potential, develop strategic plans, and capitalize on emerging opportunities in the rapidly growing Infectious Disease Diagnostics market.

The infectious disease diagnostics comprises diagnostic tests, assays, instruments, and others that are utilized for the detection and identification of causative agents responsible for the disease.

The rising prevalence of infectious diseases such as tuberculosis, influenza, hepatitis, HIV/AIDS, COVID-19, dengue, malaria, and other emerging viral and bacterial infections is significantly increasing the global demand for rapid, reliable, and accurate diagnostic solutions. The growing burden of both chronic and acute infectious diseases has intensified the need for early diagnosis to prevent disease transmission, improve patient outcomes, and reduce healthcare costs. In addition, frequent outbreaks of emerging and re-emerging pathogens, coupled with increasing global travel and urbanization, are further accelerating the requirement for efficient infectious disease surveillance and testing systems across hospitals, diagnostic laboratories, clinics, and home-care settings.

Simultaneously, rising awareness among patients, healthcare professionals, and public health organizations regarding the importance of early disease detection and preventive healthcare is supporting the wider adoption of infectious disease diagnostic tests. Governments and international health agencies are increasingly implementing large-scale screening initiatives, vaccination monitoring programs, public health campaigns, and disease surveillance strategies to control infection spread and strengthen healthcare preparedness. These initiatives are particularly prominent in developing economies where improving healthcare access and diagnostic infrastructure are becoming major priorities.

Moreover, continuous product development and technological advancements by diagnostic manufacturers are transforming the infectious disease diagnostics landscape. Companies are actively introducing advanced molecular diagnostic technologies such as PCR-based assays, next-generation sequencing (NGS), multiplex testing platforms, AI-enabled diagnostic systems, automated analyzers, and rapid point-of-care testing kits that offer faster turnaround times, improved sensitivity, and higher diagnostic accuracy. The increasing integration of digital health technologies and portable diagnostic devices is also enhancing accessibility to testing in remote and resource-limited settings. Collectively, these factors are driving substantial growth in the infectious disease diagnostics market by increasing testing volumes, improving healthcare infrastructure, enabling timely clinical decision-making, and supporting effective disease management across both developed and emerging regions.

What are the latest infectious disease diagnostics market dynamics and trends?

The rising prevalence of infectious diseases, coupled with increased awareness and screening programs, is driving the demand for timely and accurate diagnostic solutions. As more people undergo regular testing, the need for reliable diagnostic tools grows. Additionally, the increase in product development activities worldwide is leading to advancements in diagnostic technologies, enhancing test accuracy, speed, and accessibility.

According to the latest stats provided by the World Health Organization

  • Tuberculosis (TB): In 2024, an estimated 10.7 million people fell ill with TB worldwide. Diagnostics play a crucial role in quickly identifying active TB cases, enabling prompt treatment and reducing transmission risk. Screening for latent TB infection (LTBI) with tools like tuberculin skin tests and interferon-gamma release assays helps prevent disease activation. Molecular techniques like NAATs ensure rapid detection, including drug-resistant strains, guiding appropriate treatment, thereby boosting the infectious disease diagnostics market.
  • Hepatitis: In 2022, an estimated 254 million people were living with hepatitis B and 50 million people were living with hepatitis C worldwide, and 6000 people were newly infected with viral hepatitis each day. Infectious disease diagnostics enable the early detection of hepatitis (types A, B, C, D, and E), often before symptoms appear. Early diagnosis is critical for preventing disease progression and reducing transmission. Blood tests, liver function tests, and serological tests identify specific hepatitis viruses by detecting antigens, antibodies, or viral genetic material (e.g., HBV DNA or HCV RNA) and thereby escalate the overall market of infectious disease diagnostics across the globe.
  • HIV: In 2024, approximately 1.3 million [1.0-1.7 million] people acquired HIV across the world. HIV diagnostic tests are often bundled with tests for other sexually transmitted infections (STIs) like syphilis and hepatitis. Integrated testing increases the need for multi-disease diagnostic platforms.
  • Influenza: In 2024, there were around a billion cases of seasonal influenza annually, including 3-5 million cases of severe illness. Influenza is diagnosed using rapid influenza diagnostic tests (RIDTs) for quick results, while advanced methods like RT-PCR and other nucleic acid amplification tests (NAATs) offer higher accuracy. Additionally, viral culture and serological tests help confirm infections and study immune responses.

Thus, the development of rapid diagnostic tests (RDTs), nucleic acid amplification tests (NAATs), and point-of-care (POC) testing has improved accessibility and accuracy, driving market growth. Additionally, the rise of antimicrobial resistance has pushed healthcare systems to prioritize early pathogen identification, ensuring timely interventions. The integration of diagnostics into routine health checkups and the growing trend of multiplex testing have further amplified the infectious disease diagnostics market.

Additionally, the increasing product development activities are further boosting the overall market of infectious disease diagnostics. In January 2025, OraSure Technologies, Inc., a leader in point-of-need and home diagnostic tests and sample management solutions, announced that the Center for Biologics Evaluation and Research (CBER) of the Food and Drug Administration (FDA) had approved a labeling change to the OraQuick(R) HIV Self-Test, increasing access to HIV testing for adolescents.

Thus, the factors mentioned above are expected to boost the overall market of infectious disease diagnostics during the forecast period.

However, the risk of sample contamination during transport and storage is a major limiting factor for the infectious disease diagnostics market, as it can reduce the accuracy and reliability of test results, leading to false positives, false negatives, or inconclusive outcomes. Improper handling, inadequate packaging, temperature fluctuations, poor sterilization practices, and weak cold chain management can damage sample integrity and affect diagnostic performance, especially in molecular tests such as PCR. In addition, long transportation times, inconsistent handling protocols, and limited healthcare infrastructure in developing regions further increase contamination risks. These challenges can delay disease detection, increase operational costs, and reduce trust in diagnostic testing, thereby hindering market growth during the forecast period.

Infectious Disease Diagnostics Market Segment Analysis

Infectious Disease Diagnostics Market by Type (Products {Instruments and Reagents & Kits} and Services), Technology (Molecular Diagnostics {Polymerase chain reaction (PCR), DNA Sequencing and Next-Generation Sequencing (NGS), Nucleic Acid Amplification Tests (NAAT), and Others}, Immunodiagnostics, Microbial Cultures, and Others), Test Type (Laboratory-Based Tests and Point-of-Care (POC) Tests), Application (Viral Diseases, Bacterial Diseases, and Others), End-Users (Hospitals, Diagnostic Labs, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

Infectious Disease Diagnostics Market Regional Analysis

North America Infectious Disease Diagnostics Market Trends

North America is expected to account for the highest proportion of 41% of the infectious disease diagnostics market in 2025, out of all regions. North America is expected to dominate the infectious disease diagnostics market due to the high prevalence of infectious diseases, strong presence of leading diagnostic companies, advanced healthcare infrastructure, and increased adoption of molecular and point-of-care diagnostic technologies. In addition, favorable government initiatives, high healthcare spending, rising awareness regarding early disease detection, and continuous research and product development activities are further supporting market growth across the region.

As per the data provided by the U.S Department of Health and Human Services (2025), it was stated that about 23 million Americans visit a doctor's office or clinic seeking treatment for infections every year.

Additionally, according to the Centers for Disease Control and Prevention (2026), with more than 1.2 million Americans estimated to be living with HIV and nearly 39,000 diagnoses in 2024 in the U.S., the increasing prevalence of infectious diseases like viral flu, HIV, and hepatitis B in the United States will drive higher demand for infectious disease diagnostic testing. More cases require timely detection for effective treatment and containment, leading to increased testing in hospitals, clinics, and laboratories. Advancements in diagnostic technologies, along with public health initiatives, will further boost the need for rapid and accurate testing to prevent outbreaks and improve patient outcomes.

Moreover, various product development and launch activities in the domain of infectious disease diagnostics will further propel the market growth. In December 2023, QuidelOrtho Corporation announced that it had received 510(k) clearance from the U.S. FDA for its Savanna PCR platform and Savanna HSV 1+2/VZV test, enabling the detection and differentiation of HSV-1, HSV-2, and VZV from lesion swabs. This clearance allowed QuidelOrtho to market the platform and assay to U.S. labs performing moderate or high complexity diagnostic testing.

Thus, all the above-mentioned factors are anticipated to propel the market for infectious disease diagnostics in the United States during the forecast period from 2026 to 2034.

Europe Infectious Disease Diagnostics Market Trend

The Infectious Disease Diagnostics market in Europe is witnessing strong and sustained growth due to the rising prevalence of infectious diseases, increasing government focus on disease surveillance, and growing adoption of advanced molecular and point-of-care diagnostic technologies. The region benefits from well-established healthcare infrastructure, favorable reimbursement policies, and strong investments in research and development activities. In addition, the increasing burden of hospital-acquired infections (HAIs), antimicrobial resistance, and the growing demand for rapid and accurate diagnostic solutions are further supporting market expansion across Europe. The presence of leading diagnostic companies and continuous technological advancements in PCR, multiplex assays, and genomic testing are also accelerating market growth. Furthermore, recent product approvals and launches are strengthening the regional market. For instance, in September 2024, QIAGEN received European IVDR certification for its QIAstat-Dx syndromic testing systems and respiratory and gastrointestinal infection panels in Europe. Similarly, in 2024, Roche Diagnostics received CE marking for a new multiplex respiratory panel for detecting influenza, RSV, and SARS-CoV-2 variants. These developments are collectively boosting the growth of the infectious disease diagnostics market in Europe.

Asia-Pacific Infectious Disease Diagnostics Market Trends

The Asia Pacific (APAC) region is emerging as a major growth driver for the Infectious Disease Diagnostics market due to the rising prevalence of infectious diseases, growing population base, increasing healthcare expenditure, and improving access to diagnostic services across developing economies such as China, India, and Southeast Asian countries. Governments in the region are actively strengthening disease surveillance systems and investing in healthcare infrastructure to improve early disease detection and outbreak management. In addition, increasing awareness regarding infectious disease screening, expanding adoption of molecular diagnostics and point-of-care testing, and the growing presence of international as well as domestic diagnostic manufacturers are further accelerating market growth. Rapid urbanization, rising medical tourism, and supportive public health initiatives aimed at controlling diseases such as tuberculosis, dengue, hepatitis, influenza, and COVID-19 are also contributing significantly to the expansion of the infectious disease diagnostics market in the APAC region.

Who are the major players in the infectious disease diagnostics market?

The following are the leading companies in the infectious disease diagnostics market. These companies collectively hold the largest market share and dictate industry trends.

  • Hoffmann-La Roche Ltd.
  • Abbott Laboratories
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation
  • Thermo Fisher Scientific Inc.
  • QIAGEN
  • bioMerieux
  • Siemens Healthineers AG
  • DiaSorin S.p.A.
  • Hologic, Inc.
  • Sysmex Corporation
  • QuidelOrtho Corporation
  • Biosynex SA
  • Cardinal Health
  • Laboratory Corporation of America Holdings
  • Eurofins Scientific
  • InfeXn Laboratories Pvt Ltd.
  • Aegis Sciences Corporation
  • Meridian Bioscience, Inc.
  • BD
  • OraSure Technologies, Inc.
  • Trinity Biotech plc
  • Chembio Diagnostics, Inc.
  • Sekisui Diagnostics
  • PerkinElmer, Inc.
  • GenMark Diagnostics, Inc.
  • Seegene Inc.
  • Fujirebio Holdings, Inc.
  • Arkray, Inc.
  • SD Biosensor, Inc.
  • Mylab Discovery Solutions Pvt. Ltd.
  • Molbio Diagnostics Pvt. Ltd.
  • GenBody Inc.
  • Others

How is the competitive landscape shaping the Infectious Disease Diagnostics market?

The competitive landscape of the infectious disease diagnostics market is highly dynamic and characterized by strong competition among global and regional players focusing on technological innovation, product development, strategic collaborations, mergers & acquisitions, and geographic expansion. Major companies such as F. Hoffmann-La Roche Ltd., Abbott Laboratories, Thermo Fisher Scientific Inc., QIAGEN N.V., and bioMerieux SA are actively investing in advanced molecular diagnostics, multiplex assays, PCR technologies, and point-of-care testing solutions to strengthen their market presence. Companies are also emphasizing rapid and automated diagnostic platforms to improve testing accuracy, reduce turnaround time, and support large-scale disease screening. In addition, increasing regulatory approvals, partnerships with healthcare institutions, and expansion into emerging economies are intensifying market competition. The growing focus on AI-integrated diagnostics, syndromic testing panels, and decentralized testing solutions is further shaping the competitive environment and driving innovation across the infectious disease diagnostics market.

Recent Developmental Activities in the Infectious Disease Diagnostics Market

  • In January 2025, OraSure Technologies, Inc., a leader in point-of-need and home diagnostic tests and sample management solutions, announced that the Center for Biologics Evaluation and Research (CBER) of the Food and Drug Administration (FDA) had approved a labeling change to the OraQuick(R) HIV Self-Test, increasing access to HIV testing for adolescents.

Infectious Disease Diagnostics Market Segmentation

  • Infectious Disease Diagnostics by Type Exposure
  • Products
  • Instruments
  • Reagents & Kits
  • Services
  • Infectious Disease Diagnostics by Technology Exposure
  • Molecular Diagnostics
  • Polymerase chain reaction (PCR)
  • DNA Sequencing and Next-Generation Sequencing (NGS)
  • Nucleic Acid Amplification Tests (NAAT)
  • Others
  • Immunodiagnostics
  • Microbial Cultures
  • Others
  • Infectious Disease Diagnostics Test Type Exposure
  • Laboratory Based Tests
  • Point-of-Care (POC) Tests
  • Infectious Disease Diagnostics Application Exposure
  • Viral Diseases
  • Bacterial Diseases
  • Others
  • Infectious Disease Diagnostics End-Users Exposure
  • Hospitals
  • Diagnostic Labs
  • Others
  • Infectious Disease Diagnostics Geography Exposure
  • North America Infectious Disease Diagnostics Market
  • United States Infectious Disease Diagnostics Market
  • Canada Infectious Disease Diagnostics Market
  • Mexico Infectious Disease Diagnostics Market
  • Europe Infectious Disease Diagnostics Market
  • United Kingdom Infectious Disease Diagnostics Market
  • Germany Infectious Disease Diagnostics Market
  • France Infectious Disease Diagnostics Market
  • Italy Infectious Disease Diagnostics Market
  • Spain Infectious Disease Diagnostics Market
  • Rest of Europe Infectious Disease Diagnostics Market
  • Asia-Pacific Infectious Disease Diagnostics Market
  • China Infectious Disease Diagnostics Market
  • Japan Infectious Disease Diagnostics Market
  • India Infectious Disease Diagnostics Market
  • Australia Infectious Disease Diagnostics Market
  • South Korea Infectious Disease Diagnostics Market
  • Rest of Asia-Pacific Infectious Disease Diagnostics Market
  • Rest of the World Infectious Disease Diagnostics Market
  • South America Infectious Disease Diagnostics Market
  • Middle East Infectious Disease Diagnostics Market
  • Africa Infectious Disease Diagnostics Market

Key takeaways from the infectious disease diagnostics market report study

  • Market size analysis for the current infectious disease diagnostics market size (2025), and market forecast for 8 years (2026 to 2034)
  • Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
  • Key companies dominating the infectious disease diagnostics market.
  • Various opportunities available for the other competitors in the infectious disease diagnostics market space.
  • What are the top-performing segments in 2025? How these segments will perform in 2034?
  • Which are the top-performing regions and countries in the current infectious disease diagnostics market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for the infectious disease diagnostics market growth in the future.

Frequently Asked Questions for the Infectious Disease Diagnostics Market

1. What is the growth rate of the infectious disease diagnostics market?

  • The infectious disease diagnostics market is estimated to grow at a CAGR of 3.41% during the forecast period from 2026 to 2034.

2. What is the market for infectious disease diagnostics?

  • The global infectious disease diagnostics market is expected to increase from USD 28,338.85 million in 2025 to USD 38,155 million by 2034.

3. Which region has the highest share in the infectious disease diagnostics market?

  • North America is expected to dominate the infectious disease diagnostics market due to the high prevalence of infectious diseases, strong presence of leading diagnostic companies, advanced healthcare infrastructure, and increased adoption of molecular and point-of-care diagnostic technologies. In addition, favorable government initiatives, high healthcare spending, rising awareness regarding early disease detection, and continuous research and product development activities are further supporting market growth across the region.

4. What are the drivers for the infectious disease diagnostics market?

  • The rising prevalence of infectious diseases such as tuberculosis, influenza, hepatitis, HIV, and emerging viral infections is significantly increasing the demand for rapid and accurate diagnostic solutions worldwide. At the same time, growing awareness among patients and healthcare providers, along with government-led screening and surveillance programs, is encouraging early disease detection and routine testing, thereby expanding the adoption of infectious disease diagnostics. In addition, continuous product development activities by diagnostic companies, including the launch of advanced molecular diagnostics, point-of-care testing kits, AI-enabled platforms, and multiplex assays, are improving testing accuracy, speed, and accessibility. Collectively, these factors are driving the growth of the infectious disease diagnostics market by increasing testing volumes, enhancing healthcare infrastructure, and supporting timely disease management across both developed and emerging regions.

5. Who are the key players operating in the infectious disease diagnostics market?

  • Some of the key market players operating in the infectious disease diagnostics market include Hoffmann-La Roche Ltd., Abbott Laboratories, Bio-Rad Laboratories, Inc., Danaher Corporation, Thermo Fisher Scientific Inc., QIAGEN, bioMerieux, Siemens Healthineers AG, DiaSorin S.p.A., Hologic, Inc., Sysmex Corporation, QuidelOrtho Corporation, Biosynex SA, Cardinal Health, Laboratory Corporation of America Holdings, Eurofins Scientific, InfeXn Laboratories Pvt Ltd., Aegis Sciences Corporation, Meridian Bioscience, Inc., BD, OraSure Technologies, Inc., Trinity Biotech plc, Chembio Diagnostics, Inc., Sekisui Diagnostics, PerkinElmer, Inc., GenMark Diagnostics, Inc., Seegene Inc., Fujirebio Holdings, Inc., Arkray, Inc., SD Biosensor, Inc., Mylab Discovery Solutions Pvt. Ltd., Molbio Diagnostics Pvt. Ltd., GenBody Inc., and others.

Table of Contents

1. Infectious Disease Diagnostics Market Report Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Segmentation
  • 1.3 Market Assumption

2. Infectious Disease Diagnostics Market Executive Summary

  • 2.1 Market at Glance

3. Infectious Disease Diagnostics Market Key Factors Analysis

  • 3.1 Infectious Disease Diagnostics Market Drivers
    • 3.1.1 Rising prevalence of infectious diseases
    • 3.1.2 Increased awareness and screening programs
    • 3.1.3 Increase in product development activities across the globe
  • 3.2 Infectious Disease Diagnostics Market Restraints and Challenges
    • 3.2.1 Risk of sample contamination during transport and storage
  • 3.3 Infectious Disease Diagnostics Market Opportunity
    • 3.3.1 Adoption of artificial intelligence (AI) and machine learning (ML) to analyze diagnostic data

4. Impact Analysis: AI, Geopolitical, Trade, and Economic Developments

5. Regulatory Analysis

  • 5.1 The United States
  • 5.2 Europe
  • 5.3 Japan
  • 5.4 China

6. Infectious Disease Diagnostics Market Porter's Five Forces Analysis

  • 6.1 Bargaining Power of Suppliers
  • 6.2 Bargaining Power of Consumers
  • 6.3 Threat of New Entrants
  • 6.4 Threat of Substitutes
  • 6.5 Competitive Rivalry

7. Infectious Disease Diagnostics Market Assessment

  • 7.1 By Type
    • 7.1.1 Products
      • 7.1.1.1 Instruments
      • 7.1.1.2 Reagents & Kits
    • 7.1.2 Services
  • 7.2 By Technology
    • 7.2.1 Molecular Diagnostics
      • 7.2.1.1 Polymerase chain reaction (PCR)
      • 7.2.1.2 DNA Sequencing and Next-Generation Sequencing (NGS)
      • 7.2.1.3 Nucleic Acid Amplification Tests (NAAT)
      • 7.2.1.4 Others
    • 7.2.2 Immunodiagnostics
    • 7.2.3 Microbial Cultures
    • 7.2.4 Others
  • 7.3 By Test Type
    • 7.3.1 Laboratory Based Tests
    • 7.3.2 Point-of-Care (POC) Tests
  • 7.4 By Application
    • 7.4.1 Viral Diseases
    • 7.4.2 Bacterial Diseases
    • 7.4.3 Others
  • 7.5 By End-Users
    • 7.5.1 Hospitals
    • 7.5.2 Diagnostic Labs
    • 7.5.3 Others
  • 7.6 By Geography
    • 7.6.1 North America
      • 7.6.1.1 United States Infectious Disease Diagnostics Market Size in USD million (2023-2034)
      • 7.6.1.2 Canada Infectious Disease Diagnostics Market Size in USD million (2023-2034)
      • 7.6.1.3 Mexico Infectious Disease Diagnostics Market Size in USD million (2023-2034)
    • 7.6.2 Europe
      • 7.6.2.1 France Infectious Disease Diagnostics Market Size in USD million (2023-2034)
      • 7.6.2.2 Germany Infectious Disease Diagnostics Market Size in USD million (2023-2034)
      • 7.6.2.3 United Kingdom Infectious Disease Diagnostics Market Size in USD million (2023-2034)
      • 7.6.2.4 Italy Infectious Disease Diagnostics Market Size in USD million (2023-2034)
      • 7.6.2.5 Spain Infectious Disease Diagnostics Market Size in USD million (2023-2034)
      • 7.6.2.6 Rest of Europe Infectious Disease Diagnostics Market Size in USD million (2023-2034)
    • 7.6.3 Asia-Pacific
      • 7.6.3.1 China Infectious Disease Diagnostics Market Size in USD million (2023-2034)
      • 7.6.3.2 Japan Infectious Disease Diagnostics Market Size in USD million (2023-2034)
      • 7.6.3.3 India Infectious Disease Diagnostics Market Size in USD million (2023-2034)
      • 7.6.3.4 Australia Infectious Disease Diagnostics Market Size in USD million (2023-2034)
      • 7.6.3.5 South Korea Infectious Disease Diagnostics Market Size in USD million (2023-2034)
      • 7.6.3.6 Rest of Asia-Pacific Infectious Disease Diagnostics Market Size in USD million (2023-2034)
    • 7.6.4 Rest of the World (RoW)
      • 7.6.4.1 Middle East Infectious Disease Diagnostics Market Size in USD million (2023-2034)
      • 7.6.4.2 Africa Infectious Disease Diagnostics Market Size in USD million (2023-2034)
      • 7.6.4.3 South America Infectious Disease Diagnostics Market Size In USD Million (2023-2034)

8. Competitive Landscape

9. Startup Funding & Investment Trends

10. Infectious Disease Diagnostics Market Company and Product Profiles

  • 10.1 Hoffmann-La Roche Ltd.
    • 10.1.1 Company Overview
    • 10.1.2 Company Snapshot
    • 10.1.3 Financial Overview
    • 10.1.4 Product Listing
    • 10.1.5 Entropy
  • 10.2 Abbott Laboratories
    • 10.2.1 Company Overview
    • 10.2.2 Company Snapshot
    • 10.2.3 Financial Overview
    • 10.2.4 Product Listing
    • 10.2.5 Entropy
  • 10.3 Bio-Rad Laboratories, Inc.
    • 10.3.1 Company Overview
    • 10.3.2 Company Snapshot
    • 10.3.3 Financial Overview
    • 10.3.4 Product Listing
    • 10.3.5 Entropy
  • 10.4 Danaher Corporation
    • 10.4.1 Company Overview
    • 10.4.2 Company Snapshot
    • 10.4.3 Financial Overview
    • 10.4.4 Product Listing
    • 10.4.5 Entropy
  • 10.5 Thermo Fisher Scientific Inc.
    • 10.5.1 Company Overview
    • 10.5.2 Company Snapshot
    • 10.5.3 Financial Overview
    • 10.5.4 Product Listing
    • 10.5.5 Entropy
  • 10.6 QIAGEN
    • 10.6.1 Company Overview
    • 10.6.2 Company Snapshot
    • 10.6.3 Financial Overview
    • 10.6.4 Product Listing
    • 10.6.5 Entropy
  • 10.7 bioMerieux
    • 10.7.1 Company Overview
    • 10.7.2 Company Snapshot
    • 10.7.3 Financial Overview
    • 10.7.4 Product Listing
    • 10.7.5 Entropy
  • 10.8 Siemens Healthineers AG
    • 10.8.1 Company Overview
    • 10.8.2 Company Snapshot
    • 10.8.3 Financial Overview
    • 10.8.4 Product Listing
    • 10.8.5 Entropy
  • 10.9 DiaSorin S.p.A.
    • 10.9.1 Company Overview
    • 10.9.2 Company Snapshot
    • 10.9.3 Financial Overview
    • 10.9.4 Product Listing
    • 10.9.5 Entropy
  • 10.10 Hologic, Inc.
    • 10.10.1 Company Overview
    • 10.10.2 Company Snapshot
    • 10.10.3 Financial Overview
    • 10.10.4 Product Listing
    • 10.10.5 Entropy
  • 10.11 Sysmex Corporation
    • 10.11.1 Company Overview
    • 10.11.2 Company Snapshot
    • 10.11.3 Financial Overview
    • 10.11.4 Product Listing
    • 10.11.5 Entropy
  • 10.12 QuidelOrtho Corporation
    • 10.12.1 Company Overview
    • 10.12.2 Company Snapshot
    • 10.12.3 Financial Overview
    • 10.12.4 Product Listing
    • 10.12.5 Entropy
  • 10.13 Biosynex SA
    • 10.13.1 Company Overview
    • 10.13.2 Company Snapshot
    • 10.13.3 Financial Overview
    • 10.13.4 Product Listing
    • 10.13.5 Entropy
  • 10.14 Cardinal Health
    • 10.14.1 Company Overview
    • 10.14.2 Company Snapshot
    • 10.14.3 Financial Overview
    • 10.14.4 Product Listing
    • 10.14.5 Entropy
  • 10.15 Laboratory Corporation of America Holdings
    • 10.15.1 Company Overview
    • 10.15.2 Company Snapshot
    • 10.15.3 Financial Overview
    • 10.15.4 Product Listing
    • 10.15.5 Entropy
  • 10.16 Eurofins Scientific
    • 10.16.1 Company Overview
    • 10.16.2 Company Snapshot
    • 10.16.3 Financial Overview
    • 10.16.4 Product Listing
    • 10.16.5 Entropy
  • 10.17 InfeXn Laboratories Pvt Ltd.
    • 10.17.1 Company Overview
    • 10.17.2 Company Snapshot
    • 10.17.3 Financial Overview
    • 10.17.4 Product Listing
    • 10.17.5 Entropy
  • 10.18 Aegis Sciences Corporation
    • 10.18.1 Company Overview
    • 10.18.2 Company Snapshot
    • 10.18.3 Financial Overview
    • 10.18.4 Product Listing
    • 10.18.5 Entropy
  • 10.19 Meridian Bioscience, Inc.
    • 10.19.1 Company Overview
    • 10.19.2 Company Snapshot
    • 10.19.3 Financial Overview
    • 10.19.4 Product Listing
    • 10.19.5 Entropy
  • 10.20 BD
    • 10.20.1 Company Overview
    • 10.20.2 Company Snapshot
    • 10.20.3 Financial Overview
    • 10.20.4 Product Listing
    • 10.20.5 Entropy
  • 10.21 OraSure Technologies, Inc.
    • 10.21.1 Company Overview
    • 10.21.2 Company Snapshot
    • 10.21.3 Financial Overview
    • 10.21.4 Product Listing
    • 10.21.5 Entropy
  • 10.22 Trinity Biotech plc.
    • 10.22.1 Company Overview
    • 10.22.2 Company Snapshot
    • 10.22.3 Financial Overview
    • 10.22.4 Product Listing
    • 10.22.5 Entropy
  • 10.23 Chembio Diagnostics, Inc.
    • 10.23.1 Company Overview
    • 10.23.2 Company Snapshot
    • 10.23.3 Financial Overview
    • 10.23.4 Product Listing
    • 10.23.5 Entropy
  • 10.24 Sekisui Diagnostics
    • 10.24.1 Company Overview
    • 10.24.2 Company Snapshot
    • 10.24.3 Financial Overview
    • 10.24.4 Product Listing
    • 10.24.5 Entropy
  • 10.25 PerkinElmer, Inc.
    • 10.25.1 Company Overview
    • 10.25.2 Company Snapshot
    • 10.25.3 Financial Overview
    • 10.25.4 Product Listing
    • 10.25.5 Entropy
  • 10.26 GenMark Diagnostics, Inc.
    • 10.26.1 Company Overview
    • 10.26.2 Company Snapshot
    • 10.26.3 Financial Overview
    • 10.26.4 Product Listing
    • 10.26.5 Entropy
  • 10.27 Seegene Inc.
    • 10.27.1 Company Overview
    • 10.27.2 Company Snapshot
    • 10.27.3 Financial Overview
    • 10.27.4 Product Listing
    • 10.27.5 Entropy
  • 10.28 Fujirebio Holdings, Inc.
    • 10.28.1 Company Overview
    • 10.28.2 Company Snapshot
    • 10.28.3 Financial Overview
    • 10.28.4 Product Listing
    • 10.28.5 Entropy
  • 10.29 Arkray, Inc.
    • 10.29.1 Company Overview
    • 10.29.2 Company Snapshot
    • 10.29.3 Financial Overview
    • 10.29.4 Product Listing
    • 10.29.5 Entropy
  • 10.30 SD Biosensor, Inc.
    • 10.30.1 Company Overview
    • 10.30.2 Company Snapshot
    • 10.30.3 Financial Overview
    • 10.30.4 Product Listing
    • 10.30.5 Entropy
  • 10.31 Mylab Discovery Solutions Pvt. Ltd.
    • 10.31.1 Company Overview
    • 10.31.2 Company Snapshot
    • 10.31.3 Financial Overview
    • 10.31.4 Product Listing
    • 10.31.5 Entropy
  • 10.32 Molbio Diagnostics Pvt. Ltd.
    • 10.32.1 Company Overview
    • 10.32.2 Company Snapshot
    • 10.32.3 Financial Overview
    • 10.32.4 Product Listing
    • 10.32.5 Entropy
  • 10.33 GenBody Inc..
    • 10.33.1 Company Overview
    • 10.33.2 Company Snapshot
    • 10.33.3 Financial Overview
    • 10.33.4 Product Listing
    • 10.33.5 Entropy

11. KOL Views

12. Project Approach

13. About DelveInsight

14. Disclaimer & Contact Us

List of Tables

  • Table 1: Infectious Disease Diagnostics Market in Global (2023-2034)
  • Table 2: Infectious Disease Diagnostics Market in Global by Type (2023-2034)
  • Table 3: Infectious Disease Diagnostics Market in Global by Technology (2023-2034)
  • Table 4: Infectious Disease Diagnostics Market in Global by Test Type (2023-2034)
  • Table 5: Infectious Disease Diagnostics Market in Global by Application (2023-2034)
  • Table 6: Infectious Disease Diagnostics Market in North End-Users (2023-2034)
  • Table 7: Infectious Disease Diagnostics Market in Global by Geography (2023-2034)
  • Table 8: Infectious Disease Diagnostics Market in North America (2023-2034)
  • Table 9: Infectious Disease Diagnostics Market in the United States (2023-2034)
  • Table 10: Infectious Disease Diagnostics Market in Canada (2023-2034)
  • Table 11: Infectious Disease Diagnostics Market in Mexico (2023-2034)
  • Table 12: Infectious Disease Diagnostics Market in Europe (2023-2034)
  • Table 13: Infectious Disease Diagnostics Market in France (2023-2034)
  • Table 14: Infectious Disease Diagnostics Market in Germany (2023-2034)
  • Table 15: Infectious Disease Diagnostics Market in United Kingdom (2023-2034)
  • Table 16: Infectious Disease Diagnostics Market in Italy (2023-2034)
  • Table 17: Infectious Disease Diagnostics Market in Spain (2023-2034)
  • Table 18: Infectious Disease Diagnostics Market in the Rest of Europe (2023-2034)
  • Table 19: Infectious Disease Diagnostics Market in Asia-Pacific (2023-2034)
  • Table 20: Infectious Disease Diagnostics Market in China (2023-2034)
  • Table 21: Infectious Disease Diagnostics Market in Japan (2023-2034)
  • Table 22: Infectious Disease Diagnostics Market in India (2023-2034)
  • Table 23: Infectious Disease Diagnostics Market in Australia (2023-2034)
  • Table 24: Infectious Disease Diagnostics Market in South Korea (2023-2034)
  • Table 25: Infectious Disease Diagnostics Market in Rest of Asia-Pacific (2023-2034)
  • Table 26: Infectious Disease Diagnostics Market in the Rest of the World (2023-2034)
  • Table 27: Infectious Disease Diagnostics Market in the Middle East (2023-2034)
  • Table 28: Infectious Disease Diagnostics Market in Africa (2023-2034)
  • Table 29: Infectious Disease Diagnostics Market in South America (2023-2034)
  • Table 30: Competitive Landscape
  • Table 31: Startup Funding & Investment Trends

List of Figures

  • Figure 1: Infectious Disease Diagnostics Market Drivers
  • Figure 2: Infectious Disease Diagnostics Market Restraints
  • Figure 3: Infectious Disease Diagnostics Market Opportunities
  • Figure 4: AI-Powered Innovations in the Infectious Disease Diagnostics Market
  • Figure 5: US Tariff Impact on Infectious Disease Diagnostics Market
  • Figure 6: Regulatory Analysis (US, EU, Japan, China)
  • Figure 7: Porter's Five Forces Analysis
  • Figure 8: Competitive Analysis
  • Figure 9: Infectious Disease Diagnostics Market in Global (2023-2034)
  • Figure 10: Infectious Disease Diagnostics Market in Global by Type (2023-2034)
  • Figure 11: Infectious Disease Diagnostics Market in Global by Technology (2023-2034)
  • Figure 12: Infectious Disease Diagnostics Market in Global by Test Type (2023-2034)
  • Figure 13: Infectious Disease Diagnostics Market in Global by Application (2023-2034)
  • Figure 14: Infectious Disease Diagnostics Market in North End-Users (2023-2034)
  • Figure 15: Infectious Disease Diagnostics Market in Global by Geography (2023-2034)
  • Figure 16: Infectious Disease Diagnostics Market in North America (2023-2034)
  • Figure 17: Infectious Disease Diagnostics Market in the United States (2023-2034)
  • Figure 18: Infectious Disease Diagnostics Market in Canada (2023-2034)
  • Figure 19: Infectious Disease Diagnostics Market in Mexico (2023-2034)
  • Figure 20: Infectious Disease Diagnostics Market in Europe (2023-2034)
  • Figure 21: Infectious Disease Diagnostics Market in France (2023-2034)
  • Figure 22: Infectious Disease Diagnostics Market in Germany (2023-2034)
  • Figure 23: Infectious Disease Diagnostics Market in United Kingdom (2023-2034)
  • Figure 24: Infectious Disease Diagnostics Market in Italy (2023-2034)
  • Figure 25: Infectious Disease Diagnostics Market in Spain (2023-2034)
  • Figure 26: Infectious Disease Diagnostics Market in the Rest of Europe (2023-2034)
  • Figure 27: Infectious Disease Diagnostics Market in Asia-Pacific (2023-2034)
  • Figure 28: Infectious Disease Diagnostics Market in China (2023-2034)
  • Figure 29: Infectious Disease Diagnostics Market in Japan (2023-2034)
  • Figure 30: Infectious Disease Diagnostics Market in India (2023-2034)
  • Figure 31: Infectious Disease Diagnostics Market in Australia (2023-2034)
  • Figure 32: Infectious Disease Diagnostics Market in South Korea (2023-2034)
  • Figure 33: Infectious Disease Diagnostics Market in Rest of Asia-Pacific (2023-2034)
  • Figure 34: Infectious Disease Diagnostics Market in the Rest of the World (2023-2034)
  • Figure 35: Infectious Disease Diagnostics Market in the Middle East (2023-2034)
  • Figure 36: Infectious Disease Diagnostics Market in Africa (2023-2034)
  • Figure 37: Infectious Disease Diagnostics Market in South America (2023-2034)
  • Figure 38: Competitive Landscape
  • Figure 39: Startup Funding & Investment Trends